Combination anastrozole and fulvestrant in metastatic breast cancer - Wikidata - wikimedia - TriplyDB

Combination anastrozole and fulvestrant in metastatic breast cancer

Combination anastrozole and fulvestrant in metastatic breast cancer

http://www.wikidata.org/entity/Q24595386

about

ABC3 Consensus Commented from the Perspective of the German Guidelines An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review Optimal management of hormone receptor positive metastatic breast cancer in 2016 Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer Current medical treatment of estrogen receptor-positive breast cancer New directions for drug-resistant breast cancer: the CDK4/6 inhibitors Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines Clinical utilities of aromatase inhibitors in breast cancer Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways ABC3 Consensus: Assessment by a German Group of Experts AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013 Combinatorial therapy discovery using mixed integer linear programming.Emerging therapies for breast cancer Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs Fulvestrant in advanced breast cancer: evidence to date and place in therapy.A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells Treatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer.The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer.Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.The Globalization of Cooperative Groups.Targeting Transcription Factors in Cancer Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.Interpreting cancer biology: refining our therapeutic algorithm in breast cancer.The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

P2860

Q26768665-41E14935-E5C7-44B9-9BDC-52E087443DC2 Q26777085-BF5C483D-1F70-4475-9786-46911D8561E7 Q26777683-5051FCA7-B9A5-4B2D-B457-E1CDEB7B8807 Q26785496-B534F0CE-A5B9-4B82-AF53-172F66F7296E Q26795751-04E2EAB4-C048-480A-9394-DB054B9FE25D Q26797396-56D00218-787C-49E2-8225-8F38447E3FA1 Q28069856-7D6EFFB2-13BE-4BE6-9BEC-33E687269655 Q28074156-B7EE35B1-DC4A-4354-9328-D2E06597C533 Q28076777-6FA8CC3C-83D1-4403-8E4C-365D49F15680 Q28080469-3347671D-23C0-4B70-AFA3-D22108C58EC5 Q28081168-6335B8E4-3BB9-4613-B7BC-AA1D8C53C9AA Q28081872-A8338EBC-B6C1-4C11-9C7D-70E8B6CC3A02 Q28084585-36F0B77D-EF6C-4F79-AB61-163EA44DC6A4 Q30315301-F716F335-67D4-4BD3-BB89-AC147A6644F6 Q30317569-B7B65FF6-EDB7-4B44-9FEC-BE6C48976C8E Q33593388-F33BF824-0C7F-4C85-BDEC-DA6325AC47BB Q33617949-A8E4A13C-D7EB-41E8-AC3B-1AAE339EB6F2 Q33880170-EF4FEECF-DD01-4D24-AE67-68F323F58177 Q33887675-099C9B15-F93E-4926-8C89-3CE6892BD5F3 Q33900807-8D9CC24D-876F-4D33-8E7D-8BE9CCD34312 Q33993400-C8811D6D-B90D-4221-A41B-DE4D26136B11 Q34253243-76550B30-97E3-4F02-A89F-D0F97C34D2BB Q34485539-998C8BA2-772A-4030-B856-EDA54EDCA1A2 Q34657786-BE3B411B-7A24-4C90-B509-1EB9D5DCA7F2 Q35000639-8871D493-8C3D-4E62-8A94-996C995D6402 Q35687540-A64C4FD2-94B7-4B93-B626-9B0A7A7D48D2 Q35827822-EFA1F48A-336A-4A7E-B171-3443BC7B8FC7 Q35945939-0688B60D-B334-4E53-9C51-9795CFC0862F Q35958082-54043FD0-CCAD-4D44-A340-16DC7BB43D21 Q36119749-D6584E1F-E14B-42EE-92D0-F80545E24B9C Q36347511-267A3F50-6684-4085-A475-EE67C2561549 Q36534686-1533E0F6-A809-4169-9EAF-0A00E8EE4CAA Q36547566-991F5D4C-BF1E-461B-AB49-5FA7C68740F0 Q36804566-18BD811B-D796-460D-90E8-8EA84D060A9E Q36903188-901CC30C-E242-44B3-A9C8-C7023FE41598 Q36903310-199B252B-FFC8-4191-9B1B-E627F6BC6E22 Q36917641-05BB6657-2160-40C9-8AEE-D44B295DADA8 Q36924682-CD3AD9C6-A9D2-4EFF-8B1B-3562A83E76F0 Q36933778-ED01FEBE-1D1A-467B-B006-67736CA6531C Q37045421-BF264751-23A9-41BC-8ABD-428BD6505ABE

P2860

Combination anastrozole and fulvestrant in metastatic breast cancer

http://www.wikidata.org/entity/Q24595386

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Combination anastrozole and fulvestrant in metastatic breast cancer

@ast

Combination anastrozole and fulvestrant in metastatic breast cancer

@en

Combination anastrozole and fulvestrant in metastatic breast cancer

@nl

type

label

Combination anastrozole and fulvestrant in metastatic breast cancer

@ast

Combination anastrozole and fulvestrant in metastatic breast cancer

@en

Combination anastrozole and fulvestrant in metastatic breast cancer

@nl

prefLabel

Combination anastrozole and fulvestrant in metastatic breast cancer

@ast

Combination anastrozole and fulvestrant in metastatic breast cancer

@en

Combination anastrozole and fulvestrant in metastatic breast cancer

@nl

P1433

Q24595386-0E68CF48-8F9B-40D9-9012-458D1F27FD1A

P1476

Q24595386-1AD03A96-F083-4D14-B99B-A9E6B461AC11

P2093

Q24595386-03CB3A87-9F18-4919-A2F3-4EA8DD4B5C68

Q24595386-0AB056D3-5F57-4E92-A3C0-745D6E45E4D4

Q24595386-59222112-FF99-4553-9000-CFE528FC37EC

Q24595386-637F4E1F-587D-4237-A0A5-8F4989839758

Q24595386-7483648A-A9AB-4CA9-9BB2-0A8312E1D2DD

Q24595386-7B4DB465-BC81-402F-BD29-EBD81939FB0E

Q24595386-B30DF133-0C07-4CE5-8B36-0DDC6BE1B5D5

Q24595386-C2FCC88A-D380-4DE7-8FF2-C689148CB702

Q24595386-D0FE95D3-89CD-4D2B-BD8B-35C22D189CA9

Q24595386-D93ADD04-46B4-4159-A373-8B4C8D769D8D

P2860

Q24595386-05CDC249-BE70-447B-ABBB-5B943168D3C7

Q24595386-0BFDB40F-9A43-4642-AB2E-0F2AE954D170

Q24595386-0DFD9ADF-911C-46EE-9B8F-E33391B21EBD

Q24595386-1C0B312F-8751-41C4-B588-5C0DBDB5EC39

Q24595386-2B6FD87B-7F8E-4B9C-B265-C69D892A55E2

Q24595386-3132F2F6-BBC4-49F3-98A5-5076F5E74DFC

Q24595386-3186A171-3483-499B-8E5F-08738F6821F7

Q24595386-5EB94F3E-E025-4EE2-8050-CA7B09645791

Q24595386-61018083-D108-432D-83EC-33D436543CB6

Q24595386-6AB88555-FCE3-41FA-B4D5-9F7687DE0CBF

P304

Q24595386-ECA3C3A7-F31C-4677-8619-DB44C47DAEAC

P31

Q24595386-CD94B9E2-8A35-4770-A16A-CC81DC001250

P3181

Q24595386-422B975D-E301-4B9A-8D77-650E46082C0D

P356

Q24595386-B97A5E39-75C3-471A-B296-E2C0FA8ECC7B

P407

Q24595386-DFD08CFE-7F9E-4997-9517-688D1D345850

P433

Q24595386-EF4DB93E-A238-4DD1-B644-AAFAC5A15E4A

P478

Q24595386-0EA31037-5398-40BA-A1CB-1A4DE31397B3

P577

Q24595386-285CE99B-1A1A-4B72-BC29-6CEFB3CB1EB4

P698

Q24595386-33563E38-7DBB-446B-8A49-9232369F515C

P932

Q24595386-5D6F64B0-AC34-46BE-8B7F-745A573B27CC

P3181

P356

P1433

The New England Journal of Medicine

P1476

Combination anastrozole and fulvestrant in metastatic breast cancer

@en

P2093

Daniel F Hayes

http://www.w3.org/2001/XMLSchema#string

Danika L Lew

http://www.w3.org/2001/XMLSchema#string

Gabriel N Hortobagyi

http://www.w3.org/2001/XMLSchema#string

Julie R Gralow

http://www.w3.org/2001/XMLSchema#string

Kathy S Albain

http://www.w3.org/2001/XMLSchema#string

Nagendra R Tirumali

http://www.w3.org/2001/XMLSchema#string

Rita S Mehta

http://www.w3.org/2001/XMLSchema#string

Robert B Livingston

http://www.w3.org/2001/XMLSchema#string

Shaker R Dakhil

http://www.w3.org/2001/XMLSchema#string

Ted A Vandenberg

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.

Survival differences among women with de novo stage IV and relapsed breast cancer.

Prednisolone improves the response to primary endocrine treatment for advanced breast cancer.

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

P304

435-444

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

433685

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1201622

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22853014

http://www.w3.org/2001/XMLSchema#string

P932

3951300

http://www.w3.org/2001/XMLSchema#string